Skip to main content

Boston Scientific Corporation

corporate_fare Company Profile

Boston Scientific Corporation

BSX·NYSE·Life Sciences·CIK 0000885725

Boston Scientific Corporation develops, manufactures, and markets medical devices globally for various interventional medical specialties. The company has been a medical technology leader for over 45 years, focusing on less-invasive medicine by providing alternatives to surgery and other traumatic medical procedures. Their solutions help medical professionals diagnose and treat a wide range of diseases and conditions, aiming to improve patient health and reduce healthcare costs. The company operates under five strategic imperatives: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth, and Develop Key Capabilities. Boston Scientific invests in its core businesses and seeks opportunities to diversify and expand into strategic, high-growth areas and new global markets, including emerging markets. Maintaining and expanding its international presence is a key part of its long-term growth strategy, aiming to increase net sales and market share, leverage physician relationships, accelerate new product launches, and access worldwide technological developments. Research and development efforts are concentrated on next-generation and novel technology offerings across multiple programs and all divisions.

Boston Scientific Corporation (NYSE:BSX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for BSX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for BSX spans 8-K, 10-Q.

Recent high-impact activity:

  • Boston Scientific Says Cyberattack Will Cause It to Miss Guidance
  • Cyberattack to Hit Q3 and Full-Year Results, Prompting Guidance Withdrawal
  • Boston Scientific Targets Partial Shipment Restoration This Week After Cyberattack
  • Cyberattack Halts Order Fulfillment at Boston Scientific, Shares Slide 4.2%
  • Boston Scientific Hit by Cyberattack Disrupting Global Operations

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$20.07B
Net Income
$2.89B
Diluted EPS
$1.94
Op. Cash Flow
$4.53B
Free Cash Flow
$3.66B
Gross Profit
$13.85B
Operating Income
$3.61B
Cash & Equivalents
$1.97B
Total Debt
$299M
Debt / Equity
0.01×
Net Margin
14.4%
Shares Outstanding
1.48B sh
Source: 10-K · filed 2026-02-17 · accession 0000885725-26-000010

Dilution Risk

Low risk

Filing-implied dilution signals for BSX, detected from its recent SEC filings · based on capital-structure filings through 2026-04-01.

1 recent capital raise

Definitive Merger Terms Filed · Merger Consideration Details

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Recent Capital Actions

  • 2026-02-27 Proposed Mixed Merger +43.85M sh

    ing: 1 Feb. 26, 2026 USD ($) shares a: Offering: a: Fee Previously Paid false a: Rule 457(a) true a: Security Type Equity a: Security Class Title Common Stock, $0.01 par value per share a: Amount Registered | shares…

  • 2026-02-26 Executed Long-term debt ↓ −$3.27B (net of 7 line items)

    yed draw term loan in an aggregate principal amount of up to $1.000 billion, which may be drawn to fund the Acquisition at Closing, and (ii) a 364-day delayed draw term loan in an aggregate principal amount of up to…

  • 2026-02-26 Executed Total debt ↓ −$3.27B (net of 7 line items)

    yed draw term loan in an aggregate principal amount of up to $1.000 billion, which may be drawn to fund the Acquisition at Closing, and (ii) a 364-day delayed draw term loan in an aggregate principal amount of up to…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.
Browse all tickers starting with B →
$43.47 +0.13% today
52-week range · as of 2026-09-08 $42.2 – $109.5
Market cap
$62.81B
Volume
29.3M (1.4× avg)
3-mo avg 20.5M
Live data · 2026-09-20 16:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BSX - Latest Insights

BSX
Sep 08, 2026, 7:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $46.74
Real-time Price: $43.47 info
Change: -$3.27 (-7%) info
Market Cap: $62.81B info
BSX
Sep 08, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $47.56
Real-time Price: $43.47 info
Change: -$4.09 (-9%) info
Market Cap: $62.81B info
BSX
Aug 31, 2026, 11:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $48.83
Real-time Price: $43.47 info
Change: -$5.36 (-11%) info
Market Cap: $62.81B info
BSX
Aug 26, 2026, 12:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $49.91
Real-time Price: $43.47 info
Change: -$6.44 (-13%) info
Market Cap: $62.81B info
BSX
Aug 26, 2026, 6:54 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $49.91
Real-time Price: $43.47 info
Change: -$6.44 (-13%) info
Market Cap: $62.81B info
BSX
Aug 26, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $49.91
Real-time Price: $43.47 info
Change: -$6.44 (-13%) info
Market Cap: $62.81B info
BSX
Aug 03, 2026, 6:32 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.12
Real-time Price: $43.47 info
Change: -$3.65 (-8%) info
Market Cap: $62.81B info
BSX
Jul 29, 2026, 11:12 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $46.63
Real-time Price: $43.47 info
Change: -$3.16 (-7%) info
Market Cap: $62.81B info
BSX
Jul 29, 2026, 10:37 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $45.36
Real-time Price: $43.47 info
Change: -$1.89 (-4%) info
Market Cap: $62.81B info
BSX
Jul 29, 2026, 6:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $46.41
Real-time Price: $43.47 info
Change: -$2.94 (-6%) info
Market Cap: $62.81B info
BSX
Jul 29, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $46.80
Real-time Price: $43.47 info
Change: -$3.33 (-7%) info
Market Cap: $62.81B info
BSX
Jul 27, 2026, 4:24 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $45.25
Real-time Price: $43.47 info
Change: -$1.78 (-4%) info
Market Cap: $62.81B info
BSX
Jul 27, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $45.51
Real-time Price: $43.47 info
Change: -$2.04 (-4%) info
Market Cap: $62.81B info
BSX
May 27, 2026, 11:34 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $52.02
Real-time Price: $43.47 info
Change: -$8.55 (-16%) info
Market Cap: $62.81B info
BSX
May 19, 2026, 6:34 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $56.16
Real-time Price: $43.47 info
Change: -$12.69 (-23%) info
Market Cap: $62.81B info
BSX
May 18, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $53.55
Real-time Price: $43.47 info
Change: -$10.08 (-19%) info
Market Cap: $62.81B info
BSX
May 18, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $53.30
Real-time Price: $43.47 info
Change: -$9.83 (-18%) info
Market Cap: $62.81B info
BSX
May 18, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $52.80
Real-time Price: $43.47 info
Change: -$9.33 (-18%) info
Market Cap: $62.81B info
BSX
Apr 22, 2026, 6:34 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $58.00
Real-time Price: $43.47 info
Change: -$14.53 (-25%) info
Market Cap: $62.81B info
BSX
Apr 22, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $60.10
Real-time Price: $43.47 info
Change: -$16.63 (-28%) info
Market Cap: $62.81B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets